Gyre Therapeutics (NASDAQ:GYRE) Reaches New 1-Year Low – What’s Next?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares hit a new 52-week low on Thursday . The stock traded as low as $6.11 and last traded at $7.80, with a volume of 347628 shares trading hands. The stock had previously closed at $7.24.

Analyst Ratings Changes

Separately, Noble Financial initiated coverage on shares of Gyre Therapeutics in a research report on Tuesday, March 11th. They issued an “outperform” rating for the company.

Gyre Therapeutics Price Performance

The stock’s fifty day moving average is $10.20 and its 200-day moving average is $11.55. The stock has a market capitalization of $703.96 million, a P/E ratio of 150.40 and a beta of 2.03.

Gyre Therapeutics (NASDAQ:GYRE) last posted its earnings results on Monday, March 17th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.03). Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%. The firm had revenue of $27.87 million during the quarter, compared to analyst estimates of $23.50 million.

Institutional Investors Weigh In On Gyre Therapeutics

Several hedge funds have recently modified their holdings of the business. GAMMA Investing LLC increased its stake in Gyre Therapeutics by 15,083.3% during the first quarter. GAMMA Investing LLC now owns 1,822 shares of the company’s stock valued at $140,000 after acquiring an additional 1,810 shares during the period. Bank of America Corp DE increased its holdings in Gyre Therapeutics by 40.4% during the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after purchasing an additional 1,996 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Gyre Therapeutics by 9.1% in the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company’s stock valued at $1,251,000 after buying an additional 8,624 shares during the last quarter. Barclays PLC raised its stake in shares of Gyre Therapeutics by 13.5% in the fourth quarter. Barclays PLC now owns 10,543 shares of the company’s stock worth $128,000 after acquiring an additional 1,255 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after purchasing an additional 913 shares during the last quarter. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.